spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  sarcomas 

 HSMN NewsFeed - 31 Jul 2026
Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Mar 2026
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2023
FDA Clears Sirius Pintuition(R) for Long-term and Soft Tissue Implantation
Devices Oncology Surgery FDA
 HSMN NewsFeed - 12 Jul 2023
Southwest Florida Proton selects RayStation
Devices Oncology
 HSMN NewsFeed - 24 Feb 2022
PANTHERx(R) Rare Selected by Aadi Bioscience to Distribute FYARRO(TM) (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for Advanced Malignant Perivascular Epithelioid Cell Neoplasm (PEComa)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 23 Apr 2021
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2020
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2018
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jul 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 30 Nov 2017
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Aug 2017
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
Diagnostics Product Launch
 HSMN NewsFeed - 13 Jul 2017
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
Devices Oncology
 HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Dec 2016
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 2 Dec 2016
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Sep 2016
CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jan 2016
CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Oct 2015
Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Feb 2015
Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2015
CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Dec 2014
CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Jul 2013
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Feb 2013
Westchester County Man Fights Rare Cancer with Proton Therapy
Devices Oncology
 HSMN NewsFeed - 22 Jan 2013
Clinical Trials Advancing Proton Therapy Research Open at the CDH Proton Center, A ProCure Center
Devices Oncology
 HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2011
BSD Medical Announces Broadening of NCCN Guidelines for the Treatment of Soft Tissue Sarcoma by Hyperthermia Combined with Chemotherapy
Devices Oncology
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2011
Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 16 Mar 2011
First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
Devices Oncology
 HSMN NewsFeed - 1 Mar 2011
Arrival of 220-Ton Cyclotron Marks a Major Milestone in Construction of Metro New York’s First Proton Therapy Center
Devices Oncology
 HSMN NewsFeed - 24 Feb 2011
BSD Medical Announces the Inclusion of Hyperthermia and Chemotherapy as a Recommended Cancer Treatment for High Risk Sarcoma in the NCCN Practice Guidelines
Devices Oncology
 HSMN NewsFeed - 19 Jan 2011
First Patients Complete Proton Therapy Treatment at CDH Proton Center, A ProCure Center
Devices Oncology
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jun 2010
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jun 2010
BSD Medical Reports Hyperthermia Use with Particle Therapy Highlighted at German Society of Radiation Oncology Meeting
Devices Oncology
 HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 7 Apr 2010
First New Jersey Proton Therapy Center Breaks Ground
Devices Oncology
 HSMN NewsFeed - 17 Mar 2010
Radiation Breakthrough Gives Breast Cancer Patients Hope in Single Dose
Devices Oncology
 HSMN NewsFeed - 18 Feb 2010
BSD Medical Announces First Swiss Installation of the BSD-2000/3D Hyperthermia System at Kantonsspital Aarau
Devices Oncology
 HSMN NewsFeed - 18 Nov 2009
Radiation Breakthrough Gives Breast Cancer Patients Hope in Single Dose
Devices Oncology
 HSMN NewsFeed - 15 Oct 2009
Institute Curie Hospital Purchases Second TomoTherapy(R) Radiation Therapy System
Devices Oncology
 HSMN NewsFeed - 8 May 2009
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Apr 2009
ARIAD Appoints Former Bristol-Myers Squibb Senior Executive as New Independent Member of Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jan 2009
ARIAD Expands Management Team with Executive Appointments in Regulatory Affairs, Manufacturing and Information Technology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2008
BSD Medical: NCCN Clinical Practice Guidelines Indicate Significantly Superior Treatment Response When Regional Hyperthermia is Added to Chemotherapy
Devices Oncology
 HSMN NewsFeed - 23 Sep 2008
BSD Medical Corp. Announces ESMO Recommends Hyperthermia as 'Standard Therapy' for Soft Tissue Sarcoma
Devices Oncology
 HSMN NewsFeed - 23 Sep 2008
Neotropix Appoints Anthony Williams, M.D., as Its Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Jul 2008
BSD Medical's Premier Cancer Treatment System Can Now Treat Children's Cancers
Devices Oncology
 HSMN NewsFeed - 9 Jul 2008
FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 May 2008
ZIOPHARM Receives FDA Orphan Drug Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2008
Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 11 Oct 2007
ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents
Devices Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 24 Sep 2007
ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients with Metastatic Sarcomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Sep 2007
University of Dusseldorf Orders BSD-2000/3D/MR Cancer Treatment System
Devices Oncology
 HSMN NewsFeed - 10 Sep 2007
ARIAD Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Oral Deforolimus
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2007
Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 12 Jul 2007
ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
Devices Oncology
 HSMN NewsFeed - 3 Jun 2007
ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2007
Results of 340 Patient Phase III Study Using BSD Medical's Cancer Therapy Systems to Be Announced at ASCO Annual Meeting
Devices Oncology
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Apr 2007
Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Dec 2006
European Medical Studies: Shorter Treatment Cycles, Improved Tumor Control and Longer Life Expectancy for Cancer Patients Treated with IOERT
Devices Oncology
 HSMN NewsFeed - 6 Dec 2006
BSD Medical Announces Completion of 340 Patient Cancer Study
Devices Oncology
 HSMN NewsFeed - 2 Nov 2006
ARIAD Presents Expanded Efficacy Data On AP23573, Novel mTOR Inhibitor, In Phase 2 Advanced Sarcoma Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2006
ARIAD Grants Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 27

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 27 additional stories matching:
sarcomas
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!